Insulet EBITDA Margin 2010-2025 | PODD
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Insulet (PODD) over the last 10 years. The current EBITDA margin for Insulet as of March 31, 2025 is .
| Insulet EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $2.20B | $0.43B | 19.32% |
| 2024-12-31 | $2.07B | $0.39B | 18.81% |
| 2024-09-30 | $1.99B | $0.38B | 19.35% |
| 2024-06-30 | $1.87B | $0.35B | 18.62% |
| 2024-03-31 | $1.78B | $0.32B | 18.18% |
| 2023-12-31 | $1.70B | $0.29B | 17.26% |
| 2023-09-30 | $1.56B | $0.21B | 13.35% |
| 2023-06-30 | $1.47B | $0.15B | 10.44% |
| 2023-03-31 | $1.37B | $0.09B | 6.80% |
| 2022-12-31 | $1.31B | $0.10B | 7.74% |
| 2022-09-30 | $1.24B | $0.13B | 10.14% |
| 2022-06-30 | $1.18B | $0.16B | 13.16% |
| 2022-03-31 | $1.14B | $0.21B | 18.21% |
| 2021-12-31 | $1.10B | $0.18B | 16.74% |
| 2021-09-30 | $1.04B | $0.14B | 13.21% |
| 2021-06-30 | $1.00B | $0.12B | 12.46% |
| 2021-03-31 | $0.96B | $0.12B | 12.42% |
| 2020-12-31 | $0.90B | $0.11B | 11.73% |
| 2020-09-30 | $0.87B | $0.12B | 13.26% |
| 2020-06-30 | $0.83B | $0.11B | 12.73% |
| 2020-03-31 | $0.78B | $0.08B | 10.57% |
| 2019-12-31 | $0.74B | $0.08B | 10.57% |
| 2019-09-30 | $0.69B | $0.07B | 10.37% |
| 2019-06-30 | $0.65B | $0.06B | 8.88% |
| 2019-03-31 | $0.60B | $0.05B | 8.67% |
| 2018-12-31 | $0.56B | $0.04B | 7.80% |
| 2018-09-30 | $0.53B | $0.03B | 4.91% |
| 2018-06-30 | $0.50B | $0.02B | 4.19% |
| 2018-03-31 | $0.49B | $0.01B | 2.67% |
| 2017-12-31 | $0.47B | $0.01B | 1.51% |
| 2017-09-30 | $0.44B | $0.00B | 0.68% |
| 2017-06-30 | $0.41B | $0.00B | 0.73% |
| 2017-03-31 | $0.39B | $0.01B | 1.29% |
| 2016-12-31 | $0.37B | $0.00B | 0.82% |
| 2016-09-30 | $0.35B | $0.00B | -1.15% |
| 2016-06-30 | $0.32B | $-0.02B | -6.50% |
| 2016-03-31 | $0.30B | $-0.03B | -11.11% |
| 2015-12-31 | $0.26B | $-0.03B | -12.50% |
| 2015-09-30 | $0.20B | $-0.02B | -10.77% |
| 2015-06-30 | $0.20B | $-0.01B | -5.03% |
| 2015-03-31 | $0.21B | $0.00B | -0.95% |
| 2014-12-31 | $0.23B | $0.00B | 1.30% |
| 2014-09-30 | $0.29B | $0.00B | 0.70% |
| 2014-06-30 | $0.27B | $-0.01B | -4.43% |
| 2014-03-31 | $0.26B | $-0.01B | -5.02% |
| 2013-12-31 | $0.25B | $-0.02B | -6.88% |
| 2013-09-30 | $0.24B | $-0.02B | -9.75% |
| 2013-06-30 | $0.23B | $-0.02B | -6.52% |
| 2013-03-31 | $0.22B | $-0.02B | -9.05% |
| 2012-12-31 | $0.21B | $-0.03B | -11.79% |
| 2012-09-30 | $0.20B | $-0.03B | -14.93% |
| 2012-06-30 | $0.19B | $-0.03B | -16.23% |
| 2012-03-31 | $0.17B | $-0.04B | -20.93% |
| 2011-12-31 | $0.15B | $-0.03B | -22.37% |
| 2011-09-30 | $0.13B | $-0.04B | -30.08% |
| 2011-06-30 | $0.11B | $-0.04B | -33.63% |
| 2011-03-31 | $0.10B | $-0.03B | -30.77% |
| 2010-12-31 | $0.10B | $-0.03B | -35.05% |
| 2010-09-30 | $0.09B | $-0.03B | -32.58% |
| 2010-06-30 | $0.08B | $-0.04B | -42.17% |
| 2010-03-31 | $0.08B | $-0.04B | -54.67% |
| 2009-12-31 | $0.07B | $-0.05B | -72.73% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $20.051B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $221.464B | 25.98 |
| Boston Scientific (BSX) | United States | $155.948B | 37.25 |
| Stryker (SYK) | United States | $144.198B | 29.40 |
| EssilorLuxottica (ESLOY) | France | $136.878B | 0.00 |
| Medtronic (MDT) | Ireland | $114.582B | 16.24 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.915B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.396B | 24.77 |
| ResMed (RMD) | United States | $40.938B | 29.24 |
| Agilent Technologies (A) | United States | $32.241B | 21.02 |
| GE HealthCare Technologies (GEHC) | United States | $31.891B | 14.99 |
| Koninklijke Philips (PHG) | Netherlands | $25.479B | 16.85 |
| Terumo (TRUMY) | Japan | $25.170B | 32.69 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.929B | 11.51 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.503B | 0.00 |
| Baxter (BAX) | United States | $11.269B | 8.71 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.745B | 28.29 |
| Lantheus Holdings (LNTH) | United States | $4.882B | 12.32 |
| Perrigo (PRGO) | Ireland | $3.662B | 9.28 |
| Prestige Consumer Healthcare (PBH) | United States | $3.643B | 16.27 |
| Haemonetics (HAE) | United States | $3.592B | 16.36 |
| Envista Holdings (NVST) | United States | $3.530B | 24.22 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.136B | 23.12 |
| LeMaitre Vascular (LMAT) | United States | $1.831B | 40.93 |
| AtriCure (ATRC) | United States | $1.710B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.543B | 10.61 |
| Green Thumb Industries (GTBIF) | United States | $1.429B | 32.14 |
| Acuren (TIC) | United States | $1.340B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.181B | 11.99 |
| Phibro Animal Health (PAHC) | United States | $1.058B | 13.53 |
| Neogen (NEOG) | United States | $1.012B | 16.07 |
| BioLife Solutions (BLFS) | United States | $0.995B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.954B | 0.00 |
| InMode (INMD) | Israel | $0.868B | 8.04 |
| Kestra Medical Technologies (KMTS) | United States | $0.790B | 0.00 |
| Valneva SE (VALN) | France | $0.614B | 0.00 |
| Evolus (EOLS) | United States | $0.590B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.572B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.565B | 0.00 |
| ZimVie (ZIMV) | United States | $0.522B | 20.39 |
| Surmodics (SRDX) | United States | $0.515B | 0.00 |
| CeriBell (CBLL) | United States | $0.511B | 0.00 |
| Owens & Minor (OMI) | United States | $0.508B | 4.21 |
| SNDL (SNDL) | Canada | $0.434B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.361B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.311B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.304B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.296B | 10.88 |
| Quanterix (QTRX) | United States | $0.293B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.67 |
| Cerus (CERS) | United States | $0.243B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.239B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.234B | 19.77 |
| OraSure Technologies (OSUR) | United States | $0.225B | 0.00 |
| Omeros (OMER) | United States | $0.223B | 0.00 |
| Brainsway (BWAY) | Israel | $0.217B | 57.35 |
| Canopy Growth (CGC) | Canada | $0.215B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.215B | 0.00 |
| Biote (BTMD) | United States | $0.213B | 5.98 |
| Vireo Growth (VREOF) | United States | $0.196B | 0.00 |
| Exagen (XGN) | United States | $0.190B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.69 |
| Organigram Global (OGI) | Canada | $0.178B | 0.00 |
| High Tide (HITI) | Canada | $0.176B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.158B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.132B | 0.00 |
| Safety Shot (SHOT) | United States | $0.122B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.118B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.117B | 14.45 |
| Quipt Home Medical (QIPT) | United States | $0.100B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 12.51 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Veru (VERU) | United States | $0.072B | 0.00 |
| Agape ATP (ATPC) | $0.067B | 0.00 | |
| Apyx Medical (APYX) | United States | $0.066B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.054B | 0.00 |
| ImmuCell (ICCC) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Zynex (ZYXI) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.71 |
| Nephros (NEPH) | United States | $0.036B | 48.86 |
| Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |